TG01: Completed Phase I/II enrollment

Targovax completed enrollment of 32 patients with surgically resected pancreatic cancer in the open-label, European Phase I/II TG01-01 trial evaluating 0.7 mg intradermal TG01 plus GM-CSF and gemcitab...